Mitsubishi Tanabe has entered big pharma deals with BioInvent for an extended licensing agreement in relation to their antibodies library.
BioInvent signed the pharma deals extension to its 2009 licensing agreement with Mitsubishi Tanabe, a big pharma company, for the development of antibodies from BioInvent's n-CoDeR library.
Under the terms of the pharma deals extension, Mitsubishi Tanabe will continue to have access to BioInvent's discovery and development technology platform for a further two years and can develop up to eight antibody programmes.
BioInvent will receive an undisclosed initial fee plus annual maintenance fees and success-based milestone payments as well as royalties on commercialized products as part of the pharma deals.
Report: Partnering Deals and Alliances with Mitsubishi Tanabe
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity